"MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications ..."
Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical
Drug-Drug Interactions Caused by CYP3A4 Inductionξ
Very technical document, but it discusses the significance of using Fa2N-4 cells.
Not sure if this is the same, but here I go
Fa2N-4 CELL LINE x 1.5ml = around 480 EUR
Not sure what exactly the patent covers, but if the above is the same and there are multiple suppliers... Does this greater revenue potential for multicell?
Quarter Ended May 31, 2009 Compared to the Quarter Ended May 31, 2008
Revenue. Total revenue for the three months ended May 31,
Form the 10Q: I do not understand this low revenue can someone explain the 43K and how the new patent will increase this revenue - I do not understand the low amount.
2009 was $43,295, as compared to revenue of $44,482 for the same quarter in the prior fiscal year, a decrease of $1,187. All of the revenue for the quarter ended May 31, 2009 is from license revenue under agreements with Corning, Pfizer, and Eisai. For the quarter ended May 31, 2008, revenue consisted of license revenue totaling $43,632 under agreements with Corning, Pfizer and Eisai plus revenue of $850 from sales of cells and related media.